Jungsaemmool Masterclass Glow Base

Octinoxate, Titanium Dioxide, Homosalate, Octisalate


Jungsaemmool Beauty Co., Ltd.
Human Otc Drug
NDC 71261-025
Jungsaemmool Masterclass Glow Base also known as Octinoxate, Titanium Dioxide, Homosalate, Octisalate is a human otc drug labeled by 'Jungsaemmool Beauty Co., Ltd.'. National Drug Code (NDC) number for Jungsaemmool Masterclass Glow Base is 71261-025. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Jungsaemmool Masterclass Glow Base drug includes Homosalate - 30 mg/mL Octinoxate - 60 mg/mL Octisalate - 20 mg/mL Titanium Dioxide - 54.7 mg/mL . The currest status of Jungsaemmool Masterclass Glow Base drug is Active.

Drug Information:

Drug NDC: 71261-025
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Jungsaemmool Masterclass Glow Base
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Octinoxate, Titanium Dioxide, Homosalate, Octisalate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Jungsaemmool Beauty Co., Ltd.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:HOMOSALATE - 30 mg/mL
OCTINOXATE - 60 mg/mL
OCTISALATE - 20 mg/mL
TITANIUM DIOXIDE - 54.7 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Aug, 2022
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 14 Jun, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part352
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Jungsaemmool Beauty Co., Ltd.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:V06SV4M95S
4Y5P7MUD51
4X49Y0596W
15FIX9V2JP
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
71261-025-021 TUBE in 1 CARTON (71261-025-02) / 50 mL in 1 TUBE (71261-025-01)01 Aug, 2022N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Sunscreen

Product Elements:

Jungsaemmool masterclass glow base octinoxate, titanium dioxide, homosalate, octisalate water propanediol glycerin butylene glycol diethylhexyl 2,6-naphthalate niacinamide medium-chain triglycerides 1,2-hexanediol alcohol pentylene glycol polyhydroxystearic acid (2300 mw) vinylpyrrolidone/eicosene copolymer polysorbate 60 hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer (100000 mpa.s at 1.5%) triethoxycaprylylsilane cetyl peg/ppg-10/1 dimethicone (hlb 4) ammonium acryloyldimethyltaurate/vp copolymer dicaprylyl carbonate aluminum oxide squalane stearic acid dimethicone methyl hydrogenated rosinate aluminum hydroxide hypromellose 2208 0.45% stearoxy ether ethylhexylglycerin ammonium acryloyldimethyltaurate, dimethylacrylamide, lauryl methacrylate and laureth-4 methacrylate copolymer, trimethylolpropane triacrylate crosslinked (45000 mpa.s) neopentyl glycol diethylhexanoate sodium stearoyl glutamate ferric oxide red adenosine sodium polyacrylate (2500000 mw) ferric oxide yellow citric acid monohydrate sorbitan isostearate tert-butyl alcohol opuntia cochenillifera fruit saccharide isomerate agave tequilana leaf tocopherol hydrogenated soybean lecithin polyglyceryl-10 stearate hyaluronate sodium panthenol sodium citrate, unspecified form sodium ascorbyl phosphate .alpha.-tocopherol acetate vitamin a palmitate biotin cyanocobalamin sodium acetylated hyaluronate thiamine hydrochloride folic acid pyridoxine hyaluronic acid titanium dioxide titanium dioxide octinoxate octinoxate octisalate octisalate homosalate homosalate

Indications and Usage:

Helps prevent sunburn

Warnings:

For external use only do not use on damaged or broken skin when using this product, keep out of eyes. rinse with water to remove. stop using and ask a doctor if rash occurs.

Dosage and Administration:

Apply liberally 15 minutes before sun exposure. reapply at least every two hours sun protection measures. spending time in the sun increases your risk of skin cancer and early skin aging. to decrease this risk, regularly use a sunscreen with a broad spectrum spf of 15 of higher and other sun protection measures including: 1) limited time in the sun, especially from 10 am to 2 pm. 2) wear long-sleeve shirts, pants, hats, and sunglasses ask a doctor to use for children under 6 months

Package Label Principal Display Panel:

Image description


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.